0
0
Read Time:5 Minute, 40 Second
The Microfluidic Immunoassay Market was valued at $0.92 billion in 2023 and is projected to grow to $1.59 billion by 2031, starting from an estimated $0.98 billion in 2024, with a CAGR of 7.3% over the forecast period from 2024 to 2031.
In recent years, the demand for real-time detection in clinical diagnostics has surged due to the rising prevalence of chronic and infectious diseases. Alongside this, the need for highly sensitive, portable, and rapid immunoassay methods with enhanced accuracy is also increasing. The integration of microfluidic technology with immunoassays is addressing many of the limitations faced by traditional immunoassays in both research and clinical diagnostics. Microfluidic immunoassay technology effectively miniaturizes laboratory functions onto a chip, eliminating the need for extensive sample preparation, bulky benchtop instruments, and highly trained professionals. Its portability makes it more accessible, particularly in low-resource environments.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5034
Multiplexed Panel Detection: A Growing Trend
One of the significant trends in the microfluidic immunoassay market is the rising adoption of multiplexed panel detection. In many cases, detecting a single molecular event is insufficient to fully understand the pathophysiology of complex diseases like cancer. Moreover, relying on a single biomarker for early detection of diseases such as cancer might not capture the full scope of the disease in most patients. This has led to an increasing demand for the development of multianalyte-based diagnostic tests.
Multiplexed diagnostic testing is gaining traction due to its many advantages, including reduced reagent usage, simultaneous detection of multiple analytes, improved sensitivity, and faster reaction times. Microfluidic technology enables precise spatial control for immobilizing proteins and biomolecules within microchannels, allowing for the execution of multiplexing and multiparameter assays. As a result, microfluidic detection of multiple analytes in a single test has become a prominent trend in the market.
Numerous companies are expanding their lab-on-a-chip (LOC) portfolios by developing multi-analyte diagnostic tests. Point-of-care (POC) multi-analyte testing for infectious microorganisms can be particularly valuable, enabling rapid disease diagnosis and timely treatment initiation. In contrast, traditional lab culture-based diagnostics can take time, and a single-parametric test might not offer a comprehensive diagnosis. Delays in these processes can lead to severe consequences, such as septic shock and patient death.
Application of Microfluidic Immunoassay in Cardiology
Cardiology, a field that focuses on heart-related diseases and disorders, has seen an increasing number of patients suffering from heart disease, which accounts for 17.1% of deaths in the U.S. Microfluidic immunoassay technology offers an advanced alternative to traditional immunoassays for detecting cardiac diseases in resource-limited settings. Additionally, it provides rapid test results during emergencies. Microfluidic cartridges can detect biomarkers released into the blood following injury to the heart muscles. These biomarkers serve as critical indicators for diagnosing cardiovascular diseases.
Major players in the market, such as Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Micropoint Biotechnologies Co., Ltd. (China), and QuidelOrtho Corporation (U.S.), are offering microfluidic cartridges for detecting cardiac biomarkers such as Troponin, creatine kinase (CK-MB), D-Dimer, C-reactive protein (CRP), and myoglobin.
Recent advancements in microfluidic immunoassay research and development have focused on introducing multiplexed assays for detecting various cardiac conditions using a single cartridge, requiring minimal samples and time. Researchers are also using these multiplexed panels to gain a deeper understanding of the mechanisms behind heart diseases.
Browse in Depth @ https://www.meticulousresearch.com/product/microfluidic-immunoassay-market-5034
Insights from Microfluidic Immunoassay Market Analysis
Meticulous Research® has provided valuable insights into the future trajectory of the microfluidic immunoassay market. Projections indicate that the market could reach a value of $1.59 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031. The current focus on research and development within this market is driving innovations, enhancing R&D processes, and improving patient outcomes. Emerging trends in the market include the miniaturization and automation of assays, the rise of multiplexed detection systems, increased portability of detection devices and cartridges, and advancements in fabrication technologies.
As the global market evolves, North America is expected to hold a significant share of the microfluidic immunoassay market by 2024. Several leading industry players, such as Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), and QuidelOrtho Corporation (U.S.), have established a strong presence across multiple regions, contributing to the widespread adoption of their products. This comprehensive market analysis by Meticulous Research® provides key insights into the future landscape of the microfluidic immunoassay industry.
Conclusion
The microfluidic immunoassay market is experiencing rapid development and is expected to see significant growth in the coming years. Several factors are driving this growth, including the increasing use of microfluidic immunoassays for drug discovery and development, biomarker detection, the advantages of lab-on-chip assays over traditional immunoassays, and the growing focus on research and development within pharmaceutical and biotechnology companies. Additionally, the miniaturization of biological and chemical assays, along with the rising demand for point-of-care diagnostics, is expected to fuel market growth. Recent advancements in microfluidic immunoassay technology are further poised to create new opportunities in the marketplace.
Buy Now@ https://www.meticulousresearch.com/Checkout/80588586
Microfluidic Immunoassay Market Research Summary
| Particulars | Details |
| Number of Pages | 259 |
| Format | |
| Forecast Period | 2024-2031 |
| Base Year | 2023 |
| CAGR | 7.3% |
| Estimated Market Size (Value) | $1.59 billion by 2031 |
| Segments Covered | By Product
By Technology
By Application
By End User
|
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America, and Middle East & Africa |
| Key Companies | The key players operating in the global microfluidic immunoassay market are Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Nanomix Corporation (U.S.), Micropoint Biotechnologies Co., Ltd. (China), Biosurfit SA (Portugal), Koninklijke Philips N.V. (Netherland), NanoEnTek Inc. (South Korea), and QuidelOrtho Corporation (U.S.). |
About Meticulous Research®
Meticulous Research® is a leading provider of comprehensive market intelligence, offering actionable insights and analysis across various industries. Our reports empower businesses to make informed decisions, drive growth, and remain competitive in a rapidly evolving marketplace.
Contact:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
